Iovance Biotherapeutics, Inc.
IOVA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001425205
No open-market purchases or sales by Iovance Biotherapeutics, Inc. insiders were filed in the last 90 days; 293 institutions reported holding it in 13F filings for Q2 2026, worth $1.19B in total; no superinvestor holds it.
Superinvestors holding IOVA, Q2 2026
No superinvestor reported holding IOVA in Q2 2026.
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of IOVA each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q3 2023
0 superinvestors holding at quarter end
- Sold out
- ARK Invest
Q2 2023
1 superinvestor holding at quarter end
- Reduced
- ARK Invest (−4.1%)
Q1 2023
1 superinvestor holding at quarter end
- Reduced
- ARK Invest (−1.3%)
Q4 2022
1 superinvestor holding at quarter end
- Reduced
- ARK Invest (−64.6%)
Q3 2022
1 superinvestor holding at quarter end
- Reduced
- ARK Invest (−21.1%)
Q2 2022
1 superinvestor holding at quarter end
- Reduced
- ARK Invest (−3.4%)
Q1 2022
1 superinvestor holding at quarter end
- Reduced
- ARK Invest (−57.8%)
Q4 2021
1 superinvestor holding at quarter end
- Reduced
- ARK Invest (−38.2%)
Q3 2021
1 superinvestor holding at quarter end
- Reduced
- ARK Invest (−36.9%)
Q2 2021
1 superinvestor holding at quarter end
- Reduced
- ARK Invest (−6.5%)